FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386531053> ?p ?o ?g. }

• W4386531053 abstract "Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs). Manogepix (APX001A; active moiety) targets fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, inhibiting cell wall synthesis causing loss of viability. This open-label, multicentre, Phase 1b study in patients with AML and neutropenia (absolute neutrophil count <500 cells/μL; >10 days) undergoing chemotherapy aimed to assess tolerability, safety and pharmacokinetics (PK) of IV and PO fosmanogepix.Of 21 adult AML patients undergoing remission induction chemotherapy, 10 received IV fosmanogepix (600 mg; q24h) and 11 received oral fosmanogepix (500 mg; q24h) over 14 days, with a 28 day follow-up. Patients also received remission induction chemotherapy [sequential high-dose cytarabine and mitoxantrone (S-HAM) or 7 + 3 regimen] for AML and IFD prophylaxis (posaconazole). A two-compartmental PK model from previous studies in healthy volunteers was fitted to manogepix plasma data.Of 26 fosmanogepix-related adverse events (AEs; IV: 14; PO: 12) in 9 (42.9%) patients [IV: 5 (50%); PO: 4 (36.4%)], none were serious or resulted in fosmanogepix discontinuation. Most frequently occurring fosmanogepix-related AEs were Grade 1/2 nausea [four events in three patients (14.3%)]; vomiting, ALT increase, and delirium [two events; two patients (9.5%) each]. One patient experienced fosmanogepix-related Grade 3 hypertension. Dose-corrected geometric mean ratio of AUC (PO-to-IV) was 95%. Elimination half-lives (∼2 days) were consistent with prior studies in healthy volunteers.Fosmanogepix was safe and well tolerated in AML patients with neutropenia receiving remission induction chemotherapy. Safety and PK profiles were comparable to healthy volunteers." @default.
• W4386531053 created "2023-09-09" @default.
• W4386531053 creator A5001962624 @default.
• W4386531053 creator A5025876809 @default.
• W4386531053 creator A5057866828 @default.
• W4386531053 creator A5063409639 @default.
• W4386531053 creator A5070655188 @default.
• W4386531053 creator A5074358267 @default.
• W4386531053 creator A5075818401 @default.
• W4386531053 creator A5083864022 @default.
• W4386531053 creator A5086766354 @default.
• W4386531053 date "2023-09-08" @default.
• W4386531053 modified "2023-09-27" @default.
• W4386531053 title "Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia" @default.
• W4386531053 cites W1706843866 @default.
• W4386531053 cites W2121237805 @default.
• W4386531053 cites W2187008277 @default.
• W4386531053 cites W2612735173 @default.
• W4386531053 cites W2746687770 @default.
• W4386531053 cites W2754274550 @default.
• W4386531053 cites W2767031614 @default.
• W4386531053 cites W2969037002 @default.
• W4386531053 cites W3003600823 @default.
• W4386531053 cites W3093555016 @default.
• W4386531053 cites W3111383990 @default.
• W4386531053 cites W3112136340 @default.
• W4386531053 cites W3116787454 @default.
• W4386531053 cites W3120329100 @default.
• W4386531053 cites W3125625748 @default.
• W4386531053 cites W3129541328 @default.
• W4386531053 cites W3139419487 @default.
• W4386531053 cites W3173333152 @default.
• W4386531053 cites W3180852728 @default.
• W4386531053 cites W3194363336 @default.
• W4386531053 cites W3202074216 @default.
• W4386531053 cites W4200124722 @default.
• W4386531053 cites W4206237820 @default.
• W4386531053 cites W4220972968 @default.
• W4386531053 cites W4282020832 @default.
• W4386531053 cites W4361301291 @default.
• W4386531053 cites W4362658239 @default.
• W4386531053 doi "https://doi.org/10.1093/jac/dkad269" @default.
• W4386531053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37681450" @default.
• W4386531053 hasPublicationYear "2023" @default.
• W4386531053 type Work @default.
• W4386531053 citedByCount "0" @default.
• W4386531053 crossrefType "journal-article" @default.
• W4386531053 hasAuthorship W4386531053A5001962624 @default.
• W4386531053 hasAuthorship W4386531053A5025876809 @default.
• W4386531053 hasAuthorship W4386531053A5057866828 @default.
• W4386531053 hasAuthorship W4386531053A5063409639 @default.
• W4386531053 hasAuthorship W4386531053A5070655188 @default.
• W4386531053 hasAuthorship W4386531053A5074358267 @default.
• W4386531053 hasAuthorship W4386531053A5075818401 @default.
• W4386531053 hasAuthorship W4386531053A5083864022 @default.
• W4386531053 hasAuthorship W4386531053A5086766354 @default.
• W4386531053 hasBestOaLocation W43865310531 @default.
• W4386531053 hasConcept C112705442 @default.
• W4386531053 hasConcept C126322002 @default.
• W4386531053 hasConcept C16005928 @default.
• W4386531053 hasConcept C197934379 @default.
• W4386531053 hasConcept C2776611710 @default.
• W4386531053 hasConcept C2776694085 @default.
• W4386531053 hasConcept C2777063308 @default.
• W4386531053 hasConcept C2778041864 @default.
• W4386531053 hasConcept C2778375690 @default.
• W4386531053 hasConcept C2778496288 @default.
• W4386531053 hasConcept C2778566413 @default.
• W4386531053 hasConcept C2778715236 @default.
• W4386531053 hasConcept C2778850193 @default.
• W4386531053 hasConcept C2779548794 @default.
• W4386531053 hasConcept C2779629538 @default.
• W4386531053 hasConcept C2780580376 @default.
• W4386531053 hasConcept C2780852908 @default.
• W4386531053 hasConcept C2780873365 @default.
• W4386531053 hasConcept C2781413609 @default.
• W4386531053 hasConcept C71924100 @default.
• W4386531053 hasConcept C74133956 @default.
• W4386531053 hasConcept C90924648 @default.
• W4386531053 hasConceptScore W4386531053C112705442 @default.
• W4386531053 hasConceptScore W4386531053C126322002 @default.
• W4386531053 hasConceptScore W4386531053C16005928 @default.
• W4386531053 hasConceptScore W4386531053C197934379 @default.
• W4386531053 hasConceptScore W4386531053C2776611710 @default.
• W4386531053 hasConceptScore W4386531053C2776694085 @default.
• W4386531053 hasConceptScore W4386531053C2777063308 @default.
• W4386531053 hasConceptScore W4386531053C2778041864 @default.
• W4386531053 hasConceptScore W4386531053C2778375690 @default.
• W4386531053 hasConceptScore W4386531053C2778496288 @default.
• W4386531053 hasConceptScore W4386531053C2778566413 @default.
• W4386531053 hasConceptScore W4386531053C2778715236 @default.
• W4386531053 hasConceptScore W4386531053C2778850193 @default.
• W4386531053 hasConceptScore W4386531053C2779548794 @default.
• W4386531053 hasConceptScore W4386531053C2779629538 @default.
• W4386531053 hasConceptScore W4386531053C2780580376 @default.
• W4386531053 hasConceptScore W4386531053C2780852908 @default.
• W4386531053 hasConceptScore W4386531053C2780873365 @default.
• W4386531053 hasConceptScore W4386531053C2781413609 @default.
• W4386531053 hasConceptScore W4386531053C71924100 @default.
• W4386531053 hasConceptScore W4386531053C74133956 @default.

• next